Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin

K. Nakai, Y. Kanda, S. Mineishi, T. Saito, M. Ohnishi, H. Niiya, A. Chizuka, T. Takeuchi, H. Matsubara, M. Kami, A. Makimoto, Ryuji Tanosaki, H. Kunitoh, K. Tobinai, Y. Takaue

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5-10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58% vs 68%), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease.

Original languageEnglish
Pages (from-to)237-241
Number of pages5
JournalBone Marrow Transplantation
Volume29
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Antilymphocyte Serum
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Cytomegalovirus
Tissue Donors
Cladribine
Busulfan
Ganciclovir
Incidence
Homologous Transplantation
Opportunistic Infections
Immunosuppression
Medical Records
Rabbits
Infection

Keywords

  • Antigenemia
  • Cytomegalovirus
  • Ganciclovir
  • Hematopoietic stem cell transplantation
  • Reduced-intensity transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. / Nakai, K.; Kanda, Y.; Mineishi, S.; Saito, T.; Ohnishi, M.; Niiya, H.; Chizuka, A.; Takeuchi, T.; Matsubara, H.; Kami, M.; Makimoto, A.; Tanosaki, Ryuji; Kunitoh, H.; Tobinai, K.; Takaue, Y.

In: Bone Marrow Transplantation, Vol. 29, No. 3, 2002, p. 237-241.

Research output: Contribution to journalArticle

Nakai, K, Kanda, Y, Mineishi, S, Saito, T, Ohnishi, M, Niiya, H, Chizuka, A, Takeuchi, T, Matsubara, H, Kami, M, Makimoto, A, Tanosaki, R, Kunitoh, H, Tobinai, K & Takaue, Y 2002, 'Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin', Bone Marrow Transplantation, vol. 29, no. 3, pp. 237-241. https://doi.org/10.1038/sj/bmt/1703351
Nakai, K. ; Kanda, Y. ; Mineishi, S. ; Saito, T. ; Ohnishi, M. ; Niiya, H. ; Chizuka, A. ; Takeuchi, T. ; Matsubara, H. ; Kami, M. ; Makimoto, A. ; Tanosaki, Ryuji ; Kunitoh, H. ; Tobinai, K. ; Takaue, Y. / Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. In: Bone Marrow Transplantation. 2002 ; Vol. 29, No. 3. pp. 237-241.
@article{69491acdc4ff43aeb2f319eaeb0dc6b8,
title = "Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin",
abstract = "A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5-10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58{\%} vs 68{\%}), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease.",
keywords = "Antigenemia, Cytomegalovirus, Ganciclovir, Hematopoietic stem cell transplantation, Reduced-intensity transplantation",
author = "K. Nakai and Y. Kanda and S. Mineishi and T. Saito and M. Ohnishi and H. Niiya and A. Chizuka and T. Takeuchi and H. Matsubara and M. Kami and A. Makimoto and Ryuji Tanosaki and H. Kunitoh and K. Tobinai and Y. Takaue",
year = "2002",
doi = "10.1038/sj/bmt/1703351",
language = "English",
volume = "29",
pages = "237--241",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin

AU - Nakai, K.

AU - Kanda, Y.

AU - Mineishi, S.

AU - Saito, T.

AU - Ohnishi, M.

AU - Niiya, H.

AU - Chizuka, A.

AU - Takeuchi, T.

AU - Matsubara, H.

AU - Kami, M.

AU - Makimoto, A.

AU - Tanosaki, Ryuji

AU - Kunitoh, H.

AU - Tobinai, K.

AU - Takaue, Y.

PY - 2002

Y1 - 2002

N2 - A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5-10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58% vs 68%), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease.

AB - A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5-10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58% vs 68%), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease.

KW - Antigenemia

KW - Cytomegalovirus

KW - Ganciclovir

KW - Hematopoietic stem cell transplantation

KW - Reduced-intensity transplantation

UR - http://www.scopus.com/inward/record.url?scp=0036190883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036190883&partnerID=8YFLogxK

U2 - 10.1038/sj/bmt/1703351

DO - 10.1038/sj/bmt/1703351

M3 - Article

C2 - 11859396

AN - SCOPUS:0036190883

VL - 29

SP - 237

EP - 241

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -